Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant GC chemotherapy after radical cystectomy for LVI-positive pTanyN0M0 bladder urothelial carcinoma
ChiCTR1900024860Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gemcitabine and cisplatin in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: 3-year overall survival rate. Started Oct 2019; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR1900024860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024860.